Partner Therapeutics Announces Publication of 30-month Randomized Open Label Study of LEUKINE® in Combination with Whole Lung Lavage for Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

89% (8/9) of Patients Taking Inhaled Leukine Did Not Require Further Whole Lung Lavage in the 30-month Period

LEXINGTON, Mass., Nov. 30, 2023 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced today that the European Respiratory Journal published the results of a prospective, randomized clinical trial of Leukine in patients with moderate to severe autoimmune pulmonary alveolar proteinosis (aPAP) (DOI: 10.1183/13993003.01233-2023).

aPAP is a progressive lung disorder driven by blockage of GM-CSF signaling due to ...

Continue Reading →

30
NOV
2023

Press Release

Partner Therapeutics Announces Publication of 30-month Randomized Open Label Study of LEUKINE® in Combination with Whole Lung Lavage for Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC

Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])

European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome)